New injections aim to melt liver fat in MASH patients
NCT ID NCT07660848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 weeks. The main goal is to see if these injections can safely reduce liver fat content, measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-4729 injection and HRS9531 injection
- What this could lead to
- If successful, these injections could offer a new way to reduce liver fat and control MASH, potentially preventing progression to cirrhosis.
- What could go wrong
- This is an early Phase 2 trial with only 160 participants. The drugs may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 102218, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can a single gene therapy injection reverse fatty liver disease?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a tailored diet make a MASH drug work better?
- New shot aims to reverse liver scarring in MASH patients
- New drug aims to melt liver fat and stop scarring in MASH patients